Efficacy of Margetuximab vs Trastuzumab in Patients With Pretreated ERBB2-Positive Advanced Breast Cancer: A Phase 3 Randomized Clinical Trial

IMPORTANCE: ERRB2 (formerly HER2)–positive advanced breast cancer (ABC) remains typically incurable with optimal treatment undefined in later lines of therapy. The chimeric antibody margetuximab shares ERBB2 specificity with trastuzumab but incorporates an engineered Fc region to increase immune act...

ver descrição completa

Na minha lista:
Detalhes bibliográficos
Publicado no:JAMA Oncol
Main Authors: Rugo, Hope S., Im, Seock-Ah, Cardoso, Fatima, Cortés, Javier, Curigliano, Giuseppe, Musolino, Antonino, Pegram, Mark D., Wright, Gail S., Saura, Cristina, Escrivá-de-Romaní, Santiago, De Laurentiis, Michelino, Levy, Christelle, Brown-Glaberman, Ursa, Ferrero, Jean-Marc, de Boer, Maaike, Kim, Sung-Bae, Petráková, Katarína, Yardley, Denise A., Freedman, Orit, Jakobsen, Erik H., Kaufman, Bella, Yerushalmi, Rinat, Fasching, Peter A., Nordstrom, Jeffrey L., Bonvini, Ezio, Koenig, Scott, Edlich, Sutton, Hong, Shengyan, Rock, Edwin P., Gradishar, William J.
Formato: Artigo
Idioma:Inglês
Publicado em: American Medical Association 2021
Assuntos:
Original Investigation
Acesso em linha:https://ncbi.nlm.nih.gov/pmc/articles/PMC7823434/
https://ncbi.nlm.nih.gov/pubmed/33480963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1001/jamaoncol.2020.7932
Tags: Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!

Registos relacionados